Abstract
CM 025 demonstrated superior overall survival (OS), and improved safety and tolerability for NIVO in the treatment of previously treated aRCC pts compared with EVE based on 14-months (mos) minimum follow-up. Here, we report results with extended minimum follow-up of 87.7 mos, clinical characteristics of pts with ≥ 7 yrs of OS, and long-term OS and progression-free survival (PFS) predictions based on these data.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
